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Fractional flow reserve (FFR) has been validated as a reliable surrogate for inducible ischemia,1 supporting 
its use during invasive procedures for functional assess-
ment of coronary lesions. Landmark randomized trials have
See Editorial by Van Belle et al
demonstrated that deferral of nonsignificant lesions 
based on FFR is not only safe2 but also that FFR-guided 
Background—Penetration of fractional flow reserve (FFR) in clinical practice varies extensively, and the applicability of 
results from randomized trials is understudied. We describe the extent to which the information gained from routine FFR 
affects patient management strategy and clinical outcome.
Methods and Results—Nonselected patients undergoing coronary angiography, in which at least 1 lesion was interrogated by 
FFR, were prospectively enrolled in a multicenter registry. FFR-driven change in management strategy (medical therapy, 
revascularization, or additional stress imaging) was assessed per-lesion and per-patient, and the agreement between final and 
initial strategies was recorded. Cardiovascular death, myocardial infarction, or unplanned revascularization (MACE) at 1 
year was recorded. A total of 1293 lesions were evaluated in 918 patients (mean FFR, 0.81±0.1). Management plan changed 
in 406 patients (44.2%) and 584 lesions (45.2%). One-year MACE was 6.9%; patients in whom all lesions were deferred 
had a lower MACE rate (5.3%) than those with at least 1 lesion revascularized (7.3%) or left untreated despite FFR≤0.80 
(13.6%; log-rank P=0.014). At the lesion level, deferral of those with an FFR≤0.80 was associated with a 3.1-fold increase in 
the hazard of cardiovascular death/myocardial infarction/target lesion revascularization (P=0.012). Independent predictors 
of target lesion revascularization in the deferred lesions were proximal location of the lesion, B2/C type and FFR.
Conclusions—Routine FFR assessment of coronary lesions safely changes management strategy in almost half of the cases. Also, 
it accurately identifies patients and lesions with a low likelihood of events, in which revascularization can be safely deferred, as 
opposed to those at high risk when ischemic lesions are left untreated, thus confirming results from randomized trials.
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revascularization is associated with a better clinical outcome 
up to 2 years, when compared with standard angiography.3 
Results from the FAME 2 (Fractional Flow Reserve Versus 
Angiography for Multivessel Evaluation 2) study suggested 
that deferring the revascularization of epicardial stenosis with 
an FFR≤0.80 was associated with an 11.4% absolute increase 
in the risk of major cardiovascular events at 24 months (8.1% 
in revascularized patients versus 19.5% in medically treated), 
an hazard that was mainly driven by urgent revascularization.4
In spite of the overwhelming evidence of its potential 
clinical and economic benefits5 and strong guideline recom-
mendation,6 the adoption of FFR in the real-world is perceived 
to vary significantly. Reasons for this disparity are several, but 
most operators still do rely the most on angiographic eye-
balling to decide on the functional significance of coronary 
lesions and the need for revascularization.7
The Portuguese Study on the Evaluation of FFR-Guided 
Treatment of Coronary Disease (POST-IT) was a prospective 
registry designed to describe the patterns of the use of FFR in 
an unselected real-world population, to assess its impact on 
clinical decision making—concerning both lesion and patient 
management—and the 1-year outcome of such a strategy.
Methods
Study Design and Patient Population
The POST-IT registry was an investigator-initiated observational 
study, designed to prospectively include all patients referred for coro-
nary angiography in which at least 1 lesion was evaluated by FFR. 
All centers capable of performing FFR were invited to participate and 
there were no predefined exclusion criteria, other than the patient’s 
unwillingness to provide written informed consent and life expec-
tancy <1 year because of known noncardiovascular comorbidity. The 
decision to perform FFR was left to the operator in each case.
The study primary purpose was to evaluate the clinical outcome of 
a management strategy based on FFR evaluation of patients referred 
for angiography with suspected or confirmed obstructive coronary ar-
tery disease on routine daily practice. The impact of FFR on decision 
making (revascularization versus medical therapy versus further non-
invasive stress test), both per-lesion and per-patient, was also assessed.
Data Collection and Monitoring
Patient baseline and procedural characteristics were prospectively 
collected at the time of inclusion and recorded in a dedicated elec-
tronic case report form. To ensure the quality and reliability of the 
data, external monitoring was undertaken.
FFR Cutoff and Management Strategy
As part of the inclusion algorithm, treating physicians were asked to 
establish a management plan for each lesion (revascularization, medi-
cal therapy or noninvasive stress test) based on all available infor-
mation before and after FFR determination. Agreement between the 
final and initial strategies was recorded for each evaluated lesion and 
per-patient. There was no specific recommendation whether to use 
any of the cutoffs previously validated in randomized trials (0.75 or 
0.80). Clinical decisions were entirely left at the operators’ discretion. 
Please refer to the Data Supplement file for a detailed description.
Clinical Follow-Up and End Point Definition
Patients were followed for 12 months after the index procedure for 
the occurrence of the composite primary end point (MACE) of death 
from cardiovascular causes, myocardial infarction (MI) or new un-
planned revascularization (please refer to the Data Supplement file 
for detailed definitions of all study end points). An independent com-
mittee reviewed each reported event for consistency before final adju-
dication. For the purpose of the outcome analysis, the population was 
divided into 3 groups according to the management of lesions and 
patients in a way that they would resemble relevant populations in 
randomized trials as much as possible: group 1 consisted of patients 
in whom all lesions evaluated were deferred based on an FFR>0.80 
and no other lesions were revascularized; group 2 consisted of pa-
tients who underwent percutaneous coronary intervention (PCI) or 
coronary artery bypass grafting (CABG) of at least 1 lesion either 
during the index procedure or subsequently; and finally, patients 
in group 3 were those in whom at least 1 lesion with an FFR≤0.80 
was left untreated. A similar approach was chosen for the per-lesion 
analysis: group 1, deferred lesions with FFR>0.80; group 2, lesions 
revascularized, regardless of FFR value; and group 3, lesions with 
FFR≤0.80 who were not treated.
Statistical Analysis
Continuous variables with normal distribution were expressed as 
means and SD. Continuous variables with a non-normal distribution 
were expressed as median and interquartile range. Normality was 
tested with the Kolmogorov–Smirnov test and Q–Q Plot visual assess-
ment. Discrete variables were expressed as percentages. Agreement 
between initial and post-FFR treatment strategy was assessed by the 
Cohen κ test. Whenever necessary, comparison of baseline charac-
teristics or outcomes was performed using the χ2 test, with Yates cor-
rection when appropriate, for categorical variables, the Student t test, 
the Satterthwaite test or 1-way ANOVA for continuous variables with 
normal distribution and the Kruskal–Wallis test for continuous vari-
ables with a non-normal distribution. Unadjusted event-free survival 
was evaluated by Kaplan–Meier estimates and statistical significance 
assessed by the log-rank test. Adjusted risk estimates were obtained 
using Cox proportional hazard models, including variables found to 
differ significantly between groups on univariate analysis or deemed 
to be clinically relevant. A detailed description of these variables is 
presented in the Methods section of the Data Supplement. For all 
comparisons, a P value of <0.05 was considered statistically signifi-
cant. When appropriate, 95% confidence intervals (CIs) were calcu-
lated. Statistical analysis was performed with IBM SPSS Statistics 
version 19.0 (SPSS Inc, Chicago, IL).
Ethics and Regulation
The study was undertaken according to best clinical practices and all 
patients provided written informed consent. The protocol complies 
with the Declaration of Helsinki and was approved by institutional re-
view boards at each participating site. A registration was made on the 
WHAT IS KNOWN
•	Fractional flow reserve–guided revascularization has 
been shown to improve clinical outcomes and reduce 
costs in patients involved in clinical trials.
WHAT THE STUDY ADDS
•	Assessment of lesion severity using fractional flow 
reserve has the potential to safely change treatment 
strategy in a high proportion of cases.
•	Routine use of fractional flow reserve may reduce 
downstream need for noninvasive stress testing and 
new procedures.
•	Findings from randomized trials were reproduced 
in a real-world setting, further reinforcing the role 
of fractional flow reserve as a powerful tool for risk 
stratification and clinical decision making.
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From March 2012 to November 2013, 918 patients were 
enrolled in 19 hospitals. Inclusion rate per participating center is 
summarized in Table I in the Data Supplement. The flowchart of 
patient inclusion is shown in Figure 1, and population baseline 
characteristics are depicted in Table and in Table II in the Data 
Supplement. Despite the main indication for coronary angiog-
raphy was suspected or known stable coronary artery disease, a 
significant proportion of patients (35.4%) were enrolled in the 
setting of an acute coronary syndrome (ACS), either recent or 
ongoing. Although some differences existed between the 3 study 
groups, there was no clear clustering of adverse characteristics 
known to decisively influence hard clinical outcomes.
Lesion Characteristics and FFR Procedure
A total of 1293 lesions were evaluated (1.4 per patient). The 
main characteristics of study lesions, according to the revas-
cularization strategy, are detailed in the Table III in the Data 
Supplement. The overall success rate of the FFR procedure 
was 99.4% (1285/1293 lesions). Operator-reported reasons 
for unsuccessful FFR evaluation were the inability to cross the 
lesion with the pressure guidewire (n=4), acute target lesion 
occlusion after wiring (n=2), excessive bradycardia (n=1), and 
equipment malfunction (n=1). Average FFR was 0.81±0.10 
and decreased significantly with increasing stenosis severity 
(Figure I in the Data Supplement). Overall, target lesions were 
treated according to FFR information in 93% of the cases 
(1195/1285; Figure 2) and 154 patients (16.8%) underwent 
PCI of at least 1 lesion not evaluated by FFR during the index 
procedure.
Management Strategy
Strategy Change: Per-Patient Analysis
In as many as 406 patients (44.2%), final treatment decision 
was not consistent with the baseline plan (Cohen κ, 0.33; Figure 
3A). The proportion of patients ultimately undergoing revas-
cularization after FFR was known was higher than planned at 
baseline: it increased from 34.8% to 44.0% for PCI and from 
4.1% to 8.3% for CABG (Figure II in the Data Supplement). 
Even when patients initially considered for additional nonin-
vasive stress testing were excluded, still the absolute number 
of patients finally undergoing PCI and CABG increased (from 
319 to 321 and from 38 to 49, respectively).
Strategy Change: Per-Lesion Analysis
After FFR evaluation, management strategy changed in 45.2% 
of the lesions (584/1293). Globally (Figure 3B), the number of 
revascularized lesions (by PCI or CABG) increased from the 
initially planned 374 (28.9%) to a final 497 (38.4%).
One-Year Clinical Outcome
Per-Patient Analysis
Complete 12-month follow-up was available for 912 of 918 
patients (99.3%) and vital status was known for 916 (99.8%; 
Figure 1). Total MACE was 6.9% at 12 months in the entire 
cohort and was the lowest in group 1 patients (5.3%). The 
stepwise increase in total MACE across groups was sta-
tistically significant in an unadjusted analysis of the crude 
incidence (P=0.043, Figure 4A; Table IV in the Data Supple-
ment), but not after correction for relevant differences in base-
line characteristics (Figure 5A). The pattern was similar when 
only ischemia-driven events were considered. Freedom from 
the primary end point at 12 months was 94.6% in patients in 
whom management decisions changed based on FFR versus 
91.9% in those with concordant decisions between baseline 
and post-FFR (log-rank P=0.12; Figure III in the Data Supple-
ment). The incidence of both cardiovascular death and acute 
MI was numerically lower in group 1, although the difference 
was not statistically significant. Importantly, all the end points 
related to repeat revascularization were consistently lower 
in group 1, when compared with groups 2 and 3 (Table IV 
in the Data Supplement). However, patients in group 3 had 
the highest event rate for all end points considered, with 
the exception of total mortality. The adjusted hazard of tar-
get lesion revascularization (TLR) at 12 months in group 3, 
Figure 1. Study flowchart. FFR indicates 
fractional flow reserve.
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taking revascularized patients as the reference category, was 
2.38 (95% CI, 1.05–5.43; P=0.039). The corresponding haz-
ard ratio (HR) for group 1 was 0.98 (95% CI, 0.48–1.99; 
P=0.945.). The observed differences between groups both in 
total MACE and in target lesion failure were mainly driven by 
a large increase in the hazard of revascularization events in 
group 3 (Table IV in the Data Supplement).
For the 201 patients in whom an additional stress test would 
have been undertaken (based on angiography alone), complete 
follow-up information was available for all but two, who were 
Table.  Population Baseline Characteristics According to Management Strategy: Group 1 (All Lesions Deferred), 
Group 2 (At Least 1 Lesion Revascularized), and Group 3 (At Least 1 Lesion With an FFR≤0.80 Not Treated)
Variable (%) Total (n=918) Group 1 (n=398) Group 2 (n=454) Group 3 (n=66) P Value*
Demographics
  Age, y, mean±SD 65.1±10.2 66.7±10.0 63.8±10.3 64.9±9.4 <0.001
  Male sex, n (%) 700 (76.3) 283 (71.1) 367 (80.8) 50 (75.8) 0.004
Cardiovascular risk factors, n (%)
  Diabetes mellitus 321 (35.0) 125 (31.4) 164 (36.1) 32 (48.5) 0.020
  Hypertension 741 (80.7) 333 (83.7) 361 (79.5) 47 (71.2) 0.039
  Smoking (current/former <1 y) 221 (24.1) 77 (19.3) 126 (27.8) 18 (27.3) 0.070
  High cholesterol 691 (75.8) 299 (75.5) 339 (75.3) 53 (80.3) 0.670
Previous clinical history, n (%)
  Myocardial infarction 280 (31.5) 125 (31.5) 135 (29.8) 20 (30.8) 0.843
  PCI 323 (35.2) 148 (37.2) 145 (31.9) 30 (45.5) 0.054
  CABG 29 (3.2) 13 (3.3) 12 (2.6) 4 (6.1) 0.329
  Other CVD† 75 (9.5) 30 (8.7) 39 (10.0) 6 (10.3) 0.812
  Left ventricular EF 0.170
   ≤50% 155 (16.9) 63 (15.8) 85 (18.7) 7 (10.6)
   >50% 515 (56.1) 236 (59.1) 236 (52.1) 43 (65.2)
   Unknown 248 (27.0) 99 (24.9) 133 (29.3) 16 (24.2)
Indication for angiography and clinical setting, n (%)
  Known/suspected stable CAD 556 (60.6) 238 (59.9) 268 (59.0) 50 (75.8) 0.202
  Valvular heart disease/Other 37 (4.0) 19 (4.8) 16 (3.5) 2 (3.0) 0.202
  On-going ACS 230 (25.1) 98 (24.6) 123 (27.1) 9 (13.6) 0.202
  Recent ACS 95 (10.3) 43 (10.8) 47 (10.4) 5 (7.6) 0.202
  STEMI† 55 (6.0) 29 (7.3) 25 (5.5) 1 (1.5) 0.402
  NSTEMI/UA† 40 (4.4) 14 (3.5) 22 (4.9) 4 (6.1) 0.402
Procedural and angiographic characteristics, n (%)
  No. of diseased vessels (>50%) <0.001
   1 vessel 380 (41.1) 173 (43.5) 187 (41.2) 20 (30.3)
   2 vessels 242 (26.4) 52 (13.1) 166 (36.6) 24 (36.4)
   3 vessels 102 (11.1) 14 (3.5) 73 (16.1) 15 (22.7)
  Revascularization at the index procedure <0.001
   No. of lesions evaluated‡ 1.4±0.7 1.3±0.5 1.5±0.8 1.8±0.9
   No. of deferred lesions‡ 0.9±0.8 1.3±0.5 0.4±0.7 1.6±0.8
   Any PCI 408 (44.4) … 387 (85.2)§ 21 (31.8)
See Table II in the Data Supplement file for complete information on baseline patient characteristics. ACS indicates acute coronary syndrome; 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CVD, symptomatic cardiovascular disease other than CAD; EF, ejection 
fraction; FFR, fractional flow reserve; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; and 
STEMI, ST-segment–elevation myocardial infarction.
*P values are for the comparison between management groups.
†Proportions refer to patients with evaluation of nonculprit lesions in the setting of a recent ACS (n=95).
‡Average±SD per-patient.
§The remaining patients were referred for CABG.
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alive at 1 year. A management decision that did not include 
additional testing was made based on FFR in all cases (Figure 
3). The 1-year MACE rate in this group was 6.5%, which com-
pares favorably to the reminder of the reclassified population 
(4.6%; P=0.9). In the subgroup of patients in whom all lesions 
were deferred based on FFR (n=86), 3 events occurred at 12 
months (3.5%): 2 were ad hoc revascularizations based on phy-
sician’s decision (no further evidence of ischemia or angina), 
and 1 non–ST-segment–elevation ACS with no evidence of dis-
ease progression and no subsequent intervention performed.
Per-Lesion Analysis
For the purpose of the per-lesion analysis, all fatal events of 
unknown cause were adjudicated as cardiovascular deaths and 
any ischemic events (including death) for which a detailed or 
unequivocal description was not available were considered 
possibly related to a study lesion. Results are summarized in 
Figure 4B; Table V in the Data Supplement. Taken together, 
the combined 1-year rate of cardiovascular death or MI defi-
nitely or possibly related to a study lesion was significantly 
lower in group 1 than in groups 2 and 3 (0.7% versus 2.2% 
versus 2.9%; P=0.047).
TLR occurred in 2.7% of the deferred lesions from group 
1, a rate that was similar to revascularized lesions (adjusted 
HR, 1.23; 95% CI, 0.61–2.76; P=0.496). Overall, the main rea-
son reported by investigators for performing TLR was chest 
pain interpreted as angina (52.6%), either accompanied by a 
positive noninvasive stress test or invasive evidence of disease 
Figure 2. Management of study lesions 
according to fractional flow reserve (FFR) 
values. CABG indicates coronary artery 
bypass grafting; and PCI, percutaneous 
coronary intervention.
Figure 3. Strategy change per-patient (A) and per-lesion (B). CABG indicates coronary artery bypass grafting; FFR, fractional flow reserve; 
and PCI, percutaneous coronary intervention.
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progression, or MI. Importantly, in group 1, a significant pro-
portion of events was driven by chest pain with no other evi-
dence of ischemia (21%) or simply by ad hoc operator decision 
(without associated symptoms or evidence of ischemia; Table 
VI in the Data Supplement). Both the composite of death/MI 
in relation to study lesion or TLR (adjusted HR, 3.1; 95% CI, 
1.28–7.54; P=0.012) and isolated TLR (adjusted HR, 4.7; 95% 
CI, 1.8–12.3; P=0.001) were significantly higher in group 3 
than in group 2 lesions (Figures 4B and 5C and 5D).
Predictors of TLR in All Deferred Lesions
From the 1285 lesions evaluated at baseline, 794 (61.8%) 
were deferred by operator decision: 724 (56.4%) had an 
FFR>0.80 (group 1) and in the remaining 70, FFR measured 
≤0.80 (group 3). Complete follow-up information was avail-
able for 786 (99.0%) of the lesions deferred in the index pro-
cedure, which were finally included in this subgroup analysis; 
26 events occurred in this subset, yielding a rate of TLR of 
3.1% at 1 year. The independent predictors of TLR were prox-
imal location of the lesion (HR, 5.43; 95% CI, 2.16–13.65; 
P<0.001), lesion complexity defined as American College 
of Cardiology/American Heart Association B2/C type (HR, 
2.45; 95% CI, 1.08–5.58; P=0.039), and a lower FFR value 
(HR [per unit increase], 0.003; 95% CI, 0.0–0.55; P=0.029).
Discussion
The present registry is one of the largest prospective studies 
ever performed to specifically address the impact of FFR on 
the management strategy and outcome of patients with known 
or suspected coronary artery disease undergoing coronary 
angiography.8,9 Our main findings were that (1) routinely using 
FFR during invasive procedures to guide management was 
associated with a high proportion of change in treatment deci-
sions, concerning both lesions and patients, (2) patients whose 
lesions were deferred based on an FFR>0.80 had an outcome 
that was at least as good as those for which revascularization 
was deemed necessary, and (3) lesions not revascularized 
despite an FFR≤0.80 are associated with a dire prognosis. In 
addition, we have shown that FFR was an independent predic-
tor of TLR in deferred lesions, regardless of stenosis severity, 
lesion complexity, and classic clinical risk factors such as age, 
diabetes mellitus, and presentation as ACS.
Management Strategy
The adequacy of angiography to guide decisions on the best 
management of coronary lesions has been questioned.7,10–12 
Several studies have highlighted the disagreement between 
eyeballing and surrogates of functional significance of lesions 
(such as FFR) in several subsets of patients,12 and the use of 
FFR has been shown to refine risk stratification and patient 
allocation to available treatment strategies, therefore optimiz-
ing clinical outcomes.13–15 Accordingly, our data have shown 
that a change in management strategy occurred in a large pro-
portion of patients (44.2%) and lesions (45.2%) as a direct 
consequence of FFR evaluation, without reducing the overall 
number of patients undergoing revascularization (namely by 
PCI). Three other studies reported on management strategy 
change based on FFR. In the RIPCORD (Does Routine Pres-
sure Wire Assessment Influence Management Strategy at Cor-
onary Angiography for Diagnosis of Chest Pain?) study8 and 
in the FAMOUS NSTEMI (Fractional Flow Reserve Versus 
Angiographically Guided Management to Optimise Outcomes 
in Unstable Coronary Syndromes) trial,16 the extent of change 
Figure 4. Crude incidence of 12-month outcomes per-patient (A) and per-lesion (B), according to management strategy. AMI indicates 
acute MI; CV, cardiovascular; FFR, fractional flow reserve; MACE, cardiovascular death, myocardial infarction or unplanned revasculariza-
tion; MI, myocardial infarction; and TLR, target lesion revascularization.
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was 26% and 21%, respectively, far below the one we found. 
However, in both studies, all lesions ≥30% had to be interro-
gated and a significant proportion were either <50% or >70%; 
truly intermediate lesions (50% to 70%), for which a treatment 
strategy change was more likely to occur, were less frequent, 
potentially rendering the impact of FFR less pronounced. 
However, strategy change in our cohort was similar to the 43% 
recently reported by Van Belle et al9 in a large multicenter 
prospective registry of 1075 patients whose design was closer 
to POST-IT in that only those lesions in which operators had 
doubts were included. However, there is a relevant difference in 
our study because additional imaging stress tests were allowed 
as a strategy before FFR was performed. Importantly, a final 
treatment decision was made during the index procedure in all 
the 22% of patients who would have undergone further stress 
testing. Not only these patients had a favorable outcome, par-
ticularly when all lesions were deferred based on FFR, but also 
a potential reduction in downstream costs, due to the avoidance 
of additional testing, new procedures and hospitalizations.
Importantly, as opposed to common belief, the use of FFR 
did not reduce the proportion of patients undergoing revascu-
larization, either by PCI or CABG, even when those initially 
allocated to subsequent stress tests were not considered in the 
analysis.
Patient and Lesion Study Groups
Considering the study design, with broad acceptance and 
few exclusion criteria, a significant heterogeneity in the final 
patient sample was to be expected, thus making it necessar-
ily difficult to obtain homogenous groups for evaluating the 
outcome only as a function of FFR-derived management. The 
rationale underlying our approach was to define study groups 
in a way that they would resemble relevant populations in ran-
domized trials as much as possible. As such, the deferred arm 
of the DEFER17 trial and the registry group of the FAME-24 
trial (lesions with FFR above the ischemic threshold) are rep-
resented in group 1 (comprising patients in whom all study 
lesions were deferred, despite the fact other lesions could be 
Figure 5. Kaplan–Meier estimates and adjusted hazard ratios for 12-month outcomes per-patient and per-lesion according to manage-
ment strategy. A, Cardiovascular death, myocardial infarction, or unplanned revascularization (MACE), per-patient; (B) cardiovascular 
death, myocardial infarction, or target vessel failure, per-patient; (C) cardiovascular death or myocardial infarction related to study lesion 
or target lesion revascularization (TLR), per-lesion; (D) TLR, per-lesion. FFR indicates fractional flow reserve; HR, hazard ratio; and MI, 
myocardial infarction.
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present but were not evaluated or treated), and the medical 
therapy arm of the FAME-2 trial4 is represented by group 3 
patients (in whom at least 1 lesion with an FFR≤0.80 was left 
untreated). One could argue that this division is arbitrary and 
that there were relevant disparities between groups that could 
justify differences on clinical outcome on their own, which in 
fact could be true. To adjust for these differences, adjusted HRs 
were calculated including relevant variables in the regression 
models. In addition, in the per-lesion analyses, not only were 
the study groups completely homogeneous about the manage-
ment of study lesions based on FFR values but also the out-
come measures mirrored those from the per-patient analyses.
Outcome of Deferred Lesions With FFR>0.80
Our results clearly indicate that deferring lesions with an FFR 
value above the established cutoff of 0.80 is associated with a 
low event rate at 1 year. The crude incidence of all predefined 
end points was the lowest in this group, both per-patient and 
per-lesion, with the exception of TLR in the per-lesion analysis. 
However, when only those revascularization events for which 
there was a clear indication were considered (excluding, for 
instance, ad hoc PCI of a study lesion in the absence of isch-
emia, ACS or angina), the TLR rate was actually lower than in 
groups 2 and 3. The incidence of cardiac death and TLR were 
comparable to the annualized incidence of the same end points 
reported in the deferral arm of the DEFER trial,17 and the rates of 
new unplanned revascularization and MI were roughly the same 
as those in the registry arm of the FAME-2 trial.4 Importantly, 
the absolute incidence of hard clinical end points not related to 
revascularization (cardiac death or acute MI) that could be defi-
nitely or possibly attributed to a study lesion was <1%. Over-
all, when differences in baseline characteristics were taken into 
account, the cumulative hazard of MACE for both lesions and 
patients not revascularized based on an FFR>0.80 was similar 
to the hazard of those deemed to need PCI or CABG.
Outcomes of Deferred Lesions With an FFR≤0.80
A small subgroup of lesions (n=70) and patients (n=66) were 
not revascularized because of operators’ decision, despite 
functional evaluation revealing an FFR≤0.80. The reasons for 
deferring these lesions were not clear. The fact that patients in 
this group presented less often with severe symptoms and had a 
higher prevalence of multivessel and complex disease may have 
been a justification for operators to avoid revascularization.
In the per-patient analysis, MACE rate was higher in this 
group, a difference that was essentially driven by the need for 
new unplanned revascularization, as the incidence of cardio-
vascular death or MI did not differ significantly. The main rea-
sons reported by investigators for unplanned revascularization 
procedures in this group were mostly related to documented 
ischemia, MI (that could not be attributed to other lesions), 
and disease progression (Table VI in the Data Supplement). 
The FAME-2 investigators have reported similar findings, and 
in fact, urgent revascularization drove the study primary end 
point in favor of the upfront PCI strategy in lesions with an 
FFR≤0.80.4 Notably, event rates in group 3 were similar to 
those reported in medical therapy patients of the FAME-2 trial 
(total death: 1.5% versus 0.7%, MI: 3.0% versus 3.2%; and 
any revascularization: 19.7% versus 19.5%, respectively).
The best interaction between the primary end point of 
death/MI or urgent revascularization and FFR in deferred 
lesions in FAME-2 was 0.65, far below the mean 0.75±0.07 of 
group 3 lesions in our cohort. However (as shown in Figure IV 
in the Data Supplement), there is a clear association between 
the FFR value and the adjusted hazard of hard clinical events 
at 1 year, because the risk sharply increased below 0.70.
It cannot be excluded that the high rate of unplanned revas-
cularization in group 3 could be a reflection of the nonblinded 
nature of treatment, possibly rendering treating physicians prone 
to interpret symptoms as being ischemia related and to perform 
revascularization. In the 70 lesions with an FFR≤0.80 that were 
left untreated, the crude incidence of death from cardiovascular 
cause or MI that could be definitely or possibly related to a study 
lesion was the highest among the 3 groups (2.9%), as opposed 
to lesions in group 1, which had the lowest event rate (0.7%).
The link between coronary flow impairment due to any 
given fixed stenosis and the risk of plaque instability leading 
to clinically meaningful acute thrombotic events is a matter 
of debate.18 Despite the evidence that local flow conditions in 
the neighborhood of more complex and stenotic lesions may 
facilitate plaque erosion and that plaque morphological fea-
tures known to be associated with future ACS are more fre-
quently associated with surrogates of inducible ischemia,19,20 
trials performed in the setting of stable coronary artery disease 
have failed to demonstrate that revascularization significantly 
reduces the risk of hard clinical events, such as cardiac death 
or acute MI.4,21–23 However, in many of these trials the ischemic 
burden was unknown or was only mild.21,24 In a recently pub-
lished meta-analysis of 3 randomized trials (SWISSI [Swiss 
Interventional Study on Silent Ischemia], FAME-2, and the 
nuclear substudy of the COURAGE [Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug Evaluation] 
trial) of medical therapy versus PCI including 1557 patients 
with documented ischemia or an FFR≤0.80, PCI was asso-
ciated with a significant 48% mortality reduction (95% CI, 
0.30–0.92; P=0.02) at 3 years of follow-up.25
Strengths and Limitations
Considering that barely any exclusion criteria existed and that 
there were no specific recommendations as to which patients 
to include or how to guide treatment according to FFR, our 
results truly reflect current clinical practice.
The limitations of our registry are related to its obser-
vational design. Despite adequate statistical corrections, it 
cannot be definitely ruled out that differences in clinical out-
come are not a consequence of baseline patient profile, rather 
than the adequacy of treatment based on FFR value. Only a 
matched analysis of patients and lesions with comparable risk 
could further clarify these findings; however, the small sample 
size of group 3 patients and lesions would necessary render it 
underpowered to allow meaningful conclusions.
Also, the per-lesion analysis of clinical events (namely 
cardiovascular death and MI) is limited by the fact that there 
is no way to definitively confirm that any given event is related 
with a specific lesion. However, by applying a worst-case-sce-
nario approach (meaning that whenever in doubt, events were 
attributed to the study lesion), event rates would be, at the 
most, overestimated, but by the same extent in all 3 groups.
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As stated above, the fact that FFR value was known may 
have influenced revascularization decisions in lesions not 
treated with an FFR≤0.80. Finally, a longer follow-up dura-
tion would be needed to further confirm our observations.
Conclusions
The results from our registry show that routine assessment of 
coronary lesions using FFR changes management strategy in 
a high proportion of cases. Also, they are largely confirmatory 
of seminal randomized trials and highlight the applicability 
of FFR to guide treatment of real-world patients with broad 
indications for coronary angiography. FFR accurately identi-
fied patients (and lesions) with a low likelihood of events, in 
which revascularization could be safely deferred, as opposed 
to those at high risk when ischemic lesions are left untreated.
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 FFR cut-off and Management Strategy  
 
The analysis of treatment strategy change was one of the endpoints of the study. Operators were asked 
to established and register their initial treatment strategy for each lesion and patient, based on all 
available information (including clinical setting, angiography, non-invasive tests….), before even 
performing FFR. It was stressed in the protocol that this decision should be announced before 
measuring FFR, in order to avoid bias.  The available management alternatives were as follows: 
 
1) medical therapy: meaning that patients/lesion would not warrant any further testing or 
revascularization procedures as a direct consequence of the index angiography, unless clinically 
indicated downstream during the follow up; 
 
2) revascularization: either PCI or CABG, as a direct consequence of the qualifying procedure; 
 
3) Non-invasive functional testing: meaning that patients would undergo subsequent non-invasive 
stress testing in order to better clarify management. 
 
The three alternatives were available for both baseline and final decisions and had to be recorded for 
each evaluated lesion and for the patient, as a whole. 
 
After FFR was evaluated in all lesions/vessels felt to be appropriate, investigators were asked to 
outline the final strategy. There was no specific recommendation on FFR cut-offs or on how FFR 
information should be incorporated and influence decisions. Information on whether or not both initial 
and final plans were the result of the decision from a single physician or a widened clinical discussion 
with other interventional cardiologists or cardiac surgeons was not captured.  
 
 
 Clinical Follow-up and Endpoint definition 
 
Sudden death and death from an unknown cause were considered cardiovascular for the purpose of 
the primary endpoint. Myocardial infarction was defined according to the third 2012 
ESC/ACCF/AHA/WHF universal definition of MI 1 . Target lesion failure (TLF) was defined as any 
ischemic event or new revascularization procedure, which was not planned at the time of the index 
procedure, in a lesion that was evaluated by FFR at baseline, regardless of final treatment decision 
(deferral or revascularization). Thus, both elective staged PCI and elective CABG were not considered 
as events. Target lesion revascularization was defined as the need for new unplanned 




revascularization in a lesion evaluated by FFR during the index procedure.  
 
Ischemia driven revascularization was considered as those revascularization events that were 
undertaken under non-invasive evidence of ischemia with a localizing imaging test, a new FFR <0.80 
or an acute coronary syndrome for which the lesion was considered culprit, according to the operators 
best judgment. Ischemia driven composite endpoints included ischemia driven revascularization. 
 
For each adjudicated MACE, an attempt was made to identify causality between the event and the 
lesions evaluated at the index procedure, regardless of the intervention performed, if any. The 
association was considered to be “definitive” - if proven by autopsy or clinical means – or “possible” – 
if not proven, but plausible, in the opinion of the investigator. All sudden deaths or deaths from an 
unknown cause were ultimately considered to be related to the study lesions, unless proven otherwise.   
 
 
 External Monitoring 
 
For data monitoring purposes, an independent Clinical Research Associate was hired. In each center, a 
sample of at least 20% of all cases was reviewed. In centers with <20 patients, all files were reviewed. 
Monitoring included protocol compliance, as well as quality and accuracy of eCRF completion. 
Informed consent was checked in all patients. 
 
 
 Statistical Analysis - Cox proportional hazard models 
 
Variables were included in the regression models if they were found to differ significantly between 
groups in the univariate analysis (at a p value <0.05) or if they were deemed by the investigators to be 
clinically relevant for the interpretation of the outcomes in question, despite no difference at baseline.  
 
In the per-patient analysis both the primary endpoint of one-year MACE and the composite of 
cardiovascular death/myocardial infarction/target lesion failure (reported in Figure 5, panels  A and 
B, respectively), were adjusted for age, gender, hypertension, diabetes, acute coronary syndromes and  
number of vessels with stenosis>50%. 
 
In the per-lesion analysis the hazard ratios for both the composite of cardiovascular 
death/myocardial infarction/target lesion revascularization and target lesion revascularization 
(reported in Figure 5, panels C and D, respectively) were adjusted for age, gender, hypertension, 
diabetes, acute coronary syndromes, number of vessels with stenosis>50%, location of the lesion in a 
proximal segment, B2/C type, vessel diameter and stent restenosis. In addition, FFR value was 




















Centro Hospitalar de 
Vila Nova de Gaia 
Vila Nova de Gaia 169 88 1.9 1190 14% 
Hospital de Santa Cruz - 
CHLO 
Carnaxide 104 83 1.3 1190 9% 
Hospital de Garcia de 
Orta 
Almada 87 82 1.1 648 13% 
Hospital de Santa Marta 
- Centro Hospitalar de 
Lisboa Central 
Lisboa 86 62 1.4 1199 7% 
Hospital Fernando da 
Fonseca 




Coimbra 81 78 1.0 589 14% 
Hospital do Divino 
Espirito Santo 
Ponta Delgada 70 85 0,8 415 17% 
Hospital Geral dos 
Covões - Centro 
Hospitalar de Coimbra 
Coimbra 57 73 0.8 1084 5% 
Hospital de Santa Maria 
– Centro Hospitalar de 
Lisboa Norte 
Lisboa 42 33 1.3 728 9% 
Hospital de Braga Braga 31 76 0.4 542 6% 
Hospital de São 
Teotónio 
Viseu 21 68 0.3 372 6% 
Centro Hospitalar de 
Setúbal 
Setúbal 20 54 0.4 430 5% 
Hospital de Santo André 
- Centro Hospitalar de 
Leiria-Pombal 
Leiria 18 43 0.4 331 5% 
Hospital Dr. Nélio 
Mendonça 
Funchal 15 33 0.5 121 12% 
Hospital Geral de Santo 
António - Centro 
Hospitalar do Porto 
Porto 14 54 0.3 409 3% 
Centro Hospitalar de 
São João 
Porto 12 22 0.6 347 3% 
Centro Hospitalar do 
Tâmega e Sousa 
Penafiel 3 6 0.5 28 11% 
Centro Hospitalar de 
Trás-os-Montes e Alto 
Douro - Unidade 
Hospitalar de Vila Real 
Vila Real 2 11 0.2 52 4% 
Hospital do Espírito 
Santo 
Évora 1 1 1.0 4 25% 
     918 9.2% 
 
* Number of PCIs performed in each center during the inclusion period, excluding procedures performed in acute STEMI (P-PCI).  
Ϯ This ratio is only intended to allow a quick view of the magnitude of FFR use in a given center. Although this percentage is commonly 





Supplemental Table 2.  Population baseline characteristics according to management strategy: 
Deferral Group (all lesions deferred), Revascularization Group (at least one lesion revascularized) 





















   Age (years) [mean±SD] 65.1±10.2 66.7±10.0 63.8±10.3 64.9±9,4 <0.001 
   Male Gender  [n(%)] 700 (76.3) 283 (71.1) 367 (80.8) 50 (75.8) 0.004 
   BMI (Kg/m2) [mean±SD] 27.8±4.2 27.8±4.2 27.9±4.1 27.3±4.2 0.505 
Cardiovascular risk factors [n(%)] 
   Diabetes mellitus  321 (35.0) 125 (31.4) 164 (36.1) 32 (48.5) 0.020 
   Hypertension  741 (80.7) 333 (83.7) 361 (79.5) 47 (71.2) 0.039 
   Smoking 
(current/former<1year)  
221 (24.1) 77 (19.3) 126 (27.8) 18 (27.3) 0.070 
   High Cholesterol  691 (75.8) 299 (75.5) 339 (75.3) 53 (80.3) 0.670 
Prior clinical history [n(%)] 
   Myocardial infarction 280 (31.5) 125 (31.5) 135 (29.8) 20 (30.8) 0.843 
   PCI 323 (35.2) 148 (37.2) 145 (31.9) 30 (45.5) 0.054 
   CABG   29 (3.2) 13 (3.3) 12 (2.6) 4 (6.1) 0.329 
   Other CVD   75 (9.5) 30 (8.7) 39 (10.0) 6 (10.3) 0.812 
   Left Ventricular EF        
        <=50%  155 (16.9) 63 (15.8) 85 (18.7) 7 (10.6) 
0.170         >50%  515 (56.1) 236 (59.1) 236 (52.1) 43 (65.2) 
        Unknown 248 (27.0) 99 (24.9) 133 (29.3) 16 (24.2) 
   Chronic Renal Failure   33 (3.6) 12 (3.0) 17 (3.7) 4 (6.1) 0.458 
   COPD  39 (4.3) 18 (4.5) 19 (4.2) 2 (3.0) 0.850 
Cardiovascular Medication [n(%)] 
   Any anti-platelet  727 (81.2) 310 (79.9) 362 (81.9) 55 (84.6) 0.585 
   Dual anti-platelet therapy 362 (40.5) 148 (38.1) 186 (42.2) 30 (46.2) 0.325 
   Oral anticoagulation 43 (4.8) 24 (6.2) 16 (3.6) 3 (4.7) 0.222 
   Lipid Lowering  711 (79.8) 307 (79.3) 351 (80.0) 53 (81.5) 0.913 
   Statin  699 (78.5) 303 (78.3) 345 (78.6) 51 (78.5) 0.995 
   ACEI/ARB  632 (72.5) 292 (76.4) 296 (69.3) 44 (69.8) 0.069 
   Beta-Blockers  534 (60.8) 238 (61.8) 254 (59.1) 42 (65.6) 0.514 
   Calcium Chanel Blockers  167 (19.1) 71 (18.4) 80 (18.7) 16 (25.0) 0.452 
   Nitrates  221 (25.2) 95 (24.7) 107 (24.9) 19 (29.7) 0.690 
   Other anti-ischemic drugs  60 (6.8) 28 (7.3) 27 (6.3) 5 (7.9) 0.801 
   Number of anti-anginal drugs** 1.13±0.90 1.13±0.89 1.10±0.89 1.29±1,0 0.313 
Symptom status and Non-invasive testing [n(%)] 
   Typical angina 494 (53.8) 191 (48.0) 270 (59.5) 33 (50.0) 
0.002    Atypical/non-anginal chest pain 184 (20.0) 105 (26.3) 67 (14.8) 12 (18.2) 
   Other symptoms/asymptomatic 240 (26.1) 102 (25.6) 117 (25.8) 21 (31.8) 
   CCS Angina Class (n=494)      
        I  18 (3.6) 9 (4.7) 8 (3.0) 1 (3.0) 
0.157 
        II 293 (59.7) 123 (64.7) 147 (54.6) 24 (72.7) 
        III 110 (22.3) 36 (18.8) 69 (25.6) 5 (15.2) 
        IV 70 (14.2) 22 (11.5) 45 (16.7) 3 (9.1) 
   Non invasive functional test 392 (42.7) 159 (39.9) 200 (44.1) 33 (50.0) 0.222 
   Positive functional test 330 (35.9) 130 (32.7) 175 (38.5) 25 (37.9) 0.192 
   ECG-stress test 250 (27.2) 97 (24.4) 132 (29.1) 21 (31.8) 0.210 
   Imaging functional test      
     None performed 751 (81.8) 323 (81.2) 376 (82.8) 52 (78.8) 
0.952 
     SPECT 132 (14.4) 58 (14.6) 63 (13.9) 11 (16.7) 
     Dobutamine Stress Echo 31 (3.4) 15 (3.8) 13 (2.9) 3 (4.5) 
     Perfusion MRI 4 (0.4) 2 (0.5) 2 (0.4) 0 (0.0) 






Supplemental Table 2 (Cont).  Population baseline characteristics according to management 
strategy: Deferral Group (all lesions deferred), Revascularization Group (at least one lesion 





















Indication for angiography and Clinical setting  [n(%)] 
   Known/suspected stable CAD 556 (60.6) 238 (59.9) 268 (59.0) 50 (75.8) 
0.202 
   Valvular Heart Disease/Other 37 (4.0) 19 (4.8) 16 (3.5) 2 (3.0) 
   On-going ACS 230 (25.1) 98 (24.6) 123 (27.1) 9 (13.6) 
   Recent ACS 95 (10.3) 43 (10.8) 47 (10.4) 5 (7.6) 
     STEMI§ 55 (6.0) 29 (7.3) 25 (5.5) 1 (1.5) 
0.402 
     NSTEMI/UA§ 40 (4.4) 14 (3.5) 22 (4.9) 4 (6.1) 
Procedural and Angiographic Characteristics [n(%)] 
   Rhythm      
     Sinus Rhythm 846 (92.0) 356 (89.4) 427 (94.1) 63 (95.5) 
0.053      Atrial Fibrillation/flutter 52 (5.7) 33 (8.3) 17 (3.8) 2 (3.0) 
     Pacemaker 20 (2.2) 9 (2.3) 10 (2.2) 1 (1.5) 
   Heart Rate (bpm) 68±12 68±13 69±14 67±11 0.544 
   Transradial access 548 (59.7) 248 (62.3) 249 (54.8) 51 (77.3) 0.001 
   Procedure duration (min) [IQR] 45 [30-60]  38 [28-47] 51 [33-70] 50 [32-69] <0.001 
   Fluoroscopy Time (min) [IQR] 
9.5 [5.0-14.0] 
7.0 [4.5-9.5] 12.0 [7.0-17.0] 10.1 [4.6-
15.6] 
<0.001 
   Number of diseased vessels (>50%)      
        1 vessel 380 (41.1) 173 (43.5) 187 (41.2) 20 (30.3) 
<0.001         2 vessels 242 (26.4) 52 (13.1) 166 (36.6) 24 (36.4) 
        3 vessels 102 (11.1) 14 (3.5) 73 (16.1) 15 (22.7) 
   Stenosis Severity†      
       30-49% 148 (11.4) 91 (18.2) 44 (6.5) 13 (10.8) 
<0.001 
       50-69% 738 (57.1) 343 (68.7) 332 (49.3) 63 (52.5) 
       70-89% 356 (27.5) 64 (12.8) 256 (38.0) 36 (30.0) 
       >90% 51 (3.9) 1 (0.2) 42 (6.2) 8 (6.7) 
   ACC/AHA Classification B2/C† 596 (46.2) 168 (33.8) 368 (54.6) 60 (50.4) <0.001 
   Lesion location†      
        Left Main  59 (4.6) 21 (4.2) 30 (4.5) 8 (6.7) 0.001 
        Proximal LAD 242 (18.7) 89 (17.8) 131 (19.4) 22 (18.3) 0.781 
        Any proximal lesion 430 (33.3) 172 (34.5) 223 (33.1) 35 (29.2) 0.537 
   Revascularization at the index procedure  
      Number of lesions evaluated** 1.4±0.7 1.3±0.5 1.5±0.8 1.8±0.9 <0.001 
      Number of deferred lesions**  0.9±0.8 1.3±0.5 0.4±0.7 1.6±0.8 <0.001 
       Any PCI  408 (44.4) - 387 (85.2)£ 21 (31.8) <0.001 
ACS: Acute Coronary Syndrome; CABG: Coronary Artery Bypass Graf; MI: Myocardial infarction; CVD: Symptomatic 
vascular disease other than CAD; PCI: Percutaneous Coronary Intervention; STEMI: ST-Elevation Myocardial Infarction; 
IQR: Interquartile Range (P25-P75). 
*p values are for the comparison between management groups.  
** average±SD per patient. 
§ Proportions refer to patients with evaluation of non-culprit lesions in the setting of a recent ACS (n=95) 
† Proportions refer only to the characteristics of the lesions evaluated by FFR in the index procedure in each group. 
^ Ivabradine, Nicorandil and/or Trimetazidine 





Supplemental Table 3. Baseline characteristics of study lesions according to FFR and 
management strategy (Analysis refers only to lesions for which crossing with the pressure guide-























   Documented Ischemia      
     Yes 140 (10.9) 77 (10.6) 49 (10.0) 14 (20.0) 
0.057      No 106 (8.2) 58 (8.0) 46 (9.4) 2 (2.9) 
     Unknown 1039 (80.9) 589 (81.4) 396 (80.7) 54 (771.1) 
   Known Necrosis 350 (30.9) 198 (31.0) 137 (31.8) 15 (23.4) 0.607¥ 
Indication for angiography and Clinical setting  
   Stable angina 787 (61.2) 432 (59.7) 301 (61.3) 54 (77.1) 0.016 
   On-going ACS 300 (23.3) 181 (25.0) 110 (22.4) 9 (12.9) 0.058 
   Recent ACS (non-culprit lesion) 
     STEMI 83 (6.5) 55 (7.6) 27 (5.5) 1 (1.4) 
0.138¥ 
     NSTEMI/UA 70 (5.4) 32 (4.4) 34 (6.9) 4 (5.7) 
     Other indications 45 (3.5) 24 (3.3) 19 (3.9) 2 (2.9) 0.836 
Angiographic Characteristics 
   Lesion location      
        Left Main 59 (4.6) 35 (4.8) 22 (4.5) 2 (2.9) 
<0.001 
        Left Anterior Descending 705 (54.9) 313 (43.2) 335 (68.2) 57 (81.4) 
        Circumflex 256 (19.9) 196 (27.1) 56 (11.4) 4 (5.7) 
        Right Coronary Artery 263 (20.5) 179 (24.7) 77 (15.7) 7 (10.0) 
        Bypass 2 (0.2) 1 (0.1) 1 (0.2) 0 (0) 
        Proximal LAD 240 (18.7) 124 (17.1) 99 (20.2) 17 (24.3) 0.191 
        Any proximal lesion 427 (33.2) 261 (36.0) 147 (29.9) 19 (27.1) 0.046 
   Nº of diseased vessels (>50%)       
        1 vessel 466 (36.3) 265 (36.6) 181 (36.9) 20 (28.6) 
<0.001         2 vessels 392 (30.5) 183 (25.3) 182 (37.1) 27 (38.6) 
        3 vessels 180 (14.0) 70 (9.7) 95 (19.3) 15 (21.4) 
   Stenosis Severity      
       30-49% 146 (11.4) 124 (17.1) 15 (3.1) 7 (10.0) 
<0.001 
       50-69% 735 (57.2) 499 (68.9) 196 (39.9) 40 (57.1) 
       70-89% 353 (27.5) 99 (13.7) 234 (47.7) 20 (28.6) 
       >90% 51 (4.0) 2 (0.3) 46 (9.4) 3 (4.3) 
   ACC/AHA Classification B2/C† 593 (46.2) 256 (35.4) 304 (61.9) 33 (47.8)  <0.001 
   Vessel Reference Diameter (mm)    
   [mean±SD] 
2.98±0.46 3.02±0.47 2.95±0.45 2.82±0.42 <0.001 
   Small Vessel (<2.5 mm)  417 (32.6) 214 (29.6) 173 (35.3) 30 (44.1) 0.013 
   Lesion Length      
         <10 mm 232 (18.1) 180 (25.0) 44 (9.0) 8 (11.6) 
<0.001          10-20 mm 849 (66.4) 487 (67.6) 318 (64.9) 44 (63.8) 
         >20 mm 198 (15.5) 53 (7.4) 128 (26.1) 17 (24.6) 
   Diffuse disease  186 (14.6) 55 (7.6) 109 (22.3) 22 (31.4) <0.001 
   In-Stent restenosis 72 (5.6) 44 (6.1) 25 (5.1) 3 (4.3) 0.677 
   FFR value [average±SD] 0.81±0.10 0.88±0.10 0.71±0.08 0.75±0.07 <0.001 
ACS: Acute Coronary Syndrome; CABG: Coronary Artery Bypass Graf; MI: Myocardial infarction; PCI: Percutaneous 
Coronary Intervention; STEMI: ST-Elevation Myocardial Infarction; IQR: Interquartile Range (P25-P75). 
*p values are for the comparison between groups. 
§ Proportions refer to lesions for which a revascularization decision was made.  
† Evidence of ischemia or known necrosis on non-invasive tests that it attributable to the vessel were target lesion is 
located. 
¥ Yates correction 
8 
 
Supplemental Table 4. Clinical outcome at 12 months according to management strategy: 
Deferral Group (all lesions deferred), Revascularization Group (at least one lesion revascularized) 











Group 1 Group 2 Group 3 










Primary Composite Outcome 
   MACE 63(6.9) 21(5.3) 33(7.3) 9(13.6) 0.043 
        Cardiovascular Death† 13(1.4) 5(1.3) 7(1.5) 1(1.5) 0.941 
        Acute Myocardial Infarction 16(1.8) 5(1.3) 9(2.0) 2(3.0) 0.520 
        New unplanned Revascularization 45(4.9) 14(3.6) 24(5.3) 7(10.6) 0.044 
   MACE (ischemia driven) 59(6.5) 18(4.6) 33(7.3) 8(12.1) 0.042 
Secondary Clinical Outcomes 
   Cardiovascular Death, AMI or TLF 55(6.0) 20(5.1) 26(5.8) 9(13.6) 0.024 
   Cardiovascular Death or AMI 26(2.8) 9(2.3) 14(3.1) 3(4.5) 0.537 
   Total Death† 26(2.8) 10(2.5) 15(3.3) 1(1.5) 0.632 
   Death from Coronary Causes† 11(1.2) 4(1.0) 6(1.3) 1(1.5) 0.939§ 
   Hospitalization for Coronary Causes 36(3.9) 14(3.6) 19(4.2) 3(4.5) 0.860 
   TLF (all events) 46(5.0) 15(3.8) 23(5.1) 8(12.1) 0.016 
   TLF(ischemia driven) 42(4.6) 12(3.0) 23(5.1) 7(10.6) 0.020 
   TLR (all events) 33(3.6) 11(2.8) 15(3.3) 7(10.6) 0.006 
   TLR (ischemia driven) 29(3.2) 8(2.0) 15(3.3) 6(9.1) 0.010 
 
MACE: Major Adverse Cardiovascular Events (Death from cardiovascular causes, acute myocardial infarction or TLF); 
TLF: Target Lesion Failure; TLR: Target Lesion Revascularization. AMI: Acute Myocardial Infarction 
* p values are for the comparison of crude incidences between management groups. 
§ Yates Correction. 
† Vital status and cause of death was known for N=916 patients (for 2 patients there was no follow-up information) 
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Supplemental Table 5. Clinical outcome at 12 months according to management strategy: 
Deferral Group (lesions deferred with a FFR>0.80), Revascularization Group and Not treated with 









Group 1 Group 2 Group 3 











Clinical events with definite/possible relation to a study lesion 
   Death from Cardiovascular Cause  10(0.8) 3(0.4) 6(1.2) 1(1.4) 0.465§ 
   Myocardial Infarction (AMI) 10(0.8) 2(0.3) 7(1.4)  1(1.4) 0.165§ 
   Death from cardiovascular cause or AMI† 18(1.4) 5(0.7) 11(2.2) 2(2.9) 0.047§ 
Revascularization Related Events 
   TLR (total events) 38(3.0) 19(2.7) 12(2.4) 7(10.0) 0.002 
   TLR (ischemia driven) 32(2.5) 14(2.0) 12(2.4) 6(8.6) 0.003 
Combined clinical and Revascularization Related Events  with definite/possible relation to a study lesion 
    CV Death or AMI or TLR (total events) 50(3.9) 23(3.2) 19(3.9) 8(11.4) 0.003 
    CV Death or AMI or TLR (ischemia driven) 44(3.4) 18(2.5) 19(3.9) 7(10.0) 0.004 
 
TLF: Target Lesion Failure. TLR: Target Lesion Revascularization. Ischemia driven events represent those for which 
there was a plausible evidence to justify revascularization or to adjudicate the event to the study lesion. For patients 
with more than one lesion included in the study, potential relationship to ischaemic events was assumed for only one of 
the lesions. 
* p values are for the comparison of crude incidences between management groups. 
§ Yates Correction. 
† p=0.04 for the comparison of deferral vs. revascularization groups; p>0.05 for all other comparisons between groups. 
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Supplemental Table 6. Operator reported reasons for target lesion revascularization according 
to management strategy: Deferral Group (lesions deferred with an FFR>0.80), Revascularization 

























   Isolated symptoms (stable/unstable) * 9 (23.7) 4 (21.1) 4 (33.6) 1 (14.3) 
   Symptoms and positive NIST or disease 
progression or MI 
20 (52.6) 8 (42.0) 8 (66.7) 4 (57.1) 
   Positive NIST (no symptoms) 4 (10.5) 3 (15.8) - 1 (14.3) 
   Operator’s decision (no symptoms, no 
documented ischemia) 
5 (13.2) 4 (21.1) - 1 (14.3) 
ACS: acute coronary syndromes; NIST: non-invasive stress test;  
* without reference to ischemia documentation or evidence of disease progression 
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Supplemental Figure 1. Distribution of FFR values per-lesion (A) and according to angiographic 












































Supplemental Figure 3. Clinical outcomes (cardiovascular death/myocardial infarction/any 






Supplemental Figure 4. Clinical outcomes according to FFR value in deferred lesions. Deferral 
of lesions with an FFR>0.80 (green dots, Group 1) was associated with the lowest event rate as 
opposed to those left untreated with an FFR<0.80 (red dots, Group 3) which were associated with 
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